Daily Management Review

Pfizer to sell its healthcare business in November: Sources


10/26/2017


As per Pfizer’s Chief Executive, the core reason for this divestiture is to provide a better return for shareholder’s money: its consumer healthcare is worth more outside the group than within.



According to multiple source close to the matter at hand, Pfizer plans on divesting its $15 billion plus consumer healthcare business in November through an auction.
 
Several global companies, including Reckitt Benckiser and GlaxoSmithKline have expressed interest in bidding for its business, which had a turnover of $3.4 billion last year.
 
The prospective sale, which is being led by Centerview Partners, Guggenheim Securities and Morgan Stanley, was first mooted on October 10, when Pfizer said it was considering strategic options for the unit.
 
However, sources say preliminary discussions with interested parties, including Reckitt, have already taken place.
 
Pfizer wants to get the process started before the end of 2017.
 
On Wednesday, Emma Walmsley, GSK’s Chief Executive had confirmed that she would look “carefully” at the business.
 
As per 3 sources familiar with the situation, GSK has hired Citi to represent it in the auction.
 
GSK declined to comment. Citi was not immediately available for comment.
 
As per several sources, other prospective bidders include, Sanofi, Procter & Gamble, Nestle and Johnson & Johnson.
 
Pfizer plans to send out financial information about the consumer unit to prospective buyers in around three weeks time, said one of the sources, who went on to add, the bidding process is expected to heat up early next year and is expected to be sealed around the middle of 2018.
 
As per a source, Pfizer expects to raise at least $20 billion from this divestiture, given the repertoire of brands the business has in its basket including, painkiller Advil, lip balm Chapstick and multivitamins Centrum.
 
In recent year, with consumers growing increasingly health conscious, demand for medication and the consumer health sector has been a fertile ground for deal-makers.
 
As per Ian Read, Pfizer’s Chief Executive, he intends to sell the consumer healthcare business since it isn’t an integral part to the company’s core prescription drug business and might be worth more outside the group.


References:
reuters.com
 







Science & Technology

Germany Introduces The First Ever Train To Run On 100% Hydrogen

Germany Plans On Cyber Security Research To End Reliance On U.S. Tech

Fuchsia will kill Android by 2023: Top 5 facts about the new OS

New Study Finds Goats Interact More With Happy People

More than 32 thousand "smart" houses under threat of hacker attack

Internet addiction and children: Global plague

Apple takes up to develop Apple Watch for health monitoring

Hyperloop is growing in Europe

Analysts: US gamers prefer mobile games

Google Assistant Winner Of Head-To-Head Test Of Digital Assistants, Beats Siri And Alexa

World Politics

World & Politics

Ex-Brexit Minister Said A ‘Reset’ Is Needed For Brexit Talks

10 countries with the best healthcare systems

Foreign Experts To Be Allowed By North Korea For Permanent Destruction Of Missile Sites

Ireland recovers €14.3 billion from Apple

Is China going to cancel its birth limit policy?

The US is ready to start negotiations with China

US and China start 5G race

Is Czech Republic posing a threat to the European Union?